CDC this month released updated recommendations for how people can protect themselves and their communities from respiratory viruses, including COVID-19. 

When the Minnesota legislature was debating a paid sick leave bill last year, business owners argued that such a law would not allow them to provide as many employee “perks” or be as “adaptive” to employee needs as they say they would be without such a requirement. But a half dozen witnesses made a case for the need, with many workers sharing examples of the numerous times they had to work while ill.

Despite the Centers for Disease Control and Prevention warning this year will be potentially dangerous for respiratory illnesses, a third of Americans are not concerned about the threat, according to a new national survey by The Ohio State University Wexner Medical Center.

This month, the U.S. Food and Drug Administration approved Abrysvo (Respiratory Syncytial Virus Vaccine), the first vaccine approved for use in pregnant individuals to prevent lower respiratory tract disease (LRTD) and severe LRTD caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age.

The American Academy of Pediatrics recommends that all infants — and especially those at high risk — receive the new preventive antibody, nirsevimab, to protect against severe disease caused by respiratory syncytial virus (RSV), which is common, highly contagious and sometimes deadly.

CDC is recommending a new immunization starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus (RSV).

The U.S. Food and Drug Administration last week approved Beyfortus (nirsevimab-alip) for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants born during or entering their first RSV season, and in children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.